Literature DB >> 33754011

UXT antisense RNA 1 sever as a novel prognostic long non-coding RNA in early stage pancreatic ductal adenocarcinoma patients after receiving pancreaticoduodenectomy.

Xiwen Liao1, Rui Huang2, Xiangkun Wang1, Ketuan Huang1, Chengkun Yang1, Xin Zhou1, Chuangye Han1, Hao Su1, Xinping Ye1, Kang Liu3, Guangzhi Zhu1, Tao Peng1.   

Abstract

Objective: The principal objective of this project was to investigate the prognostic value of UXT antisense RNA 1 (UXT-AS1) in pancreatic ductal adenocarcinoma (PDAC), as well as its biological function mechanisms and the screening of targeted drugs using The Cancer Genome Atlas (TCGA) PDAC genome-wide RNA sequencing (RNA-seq) dataset.
Methods: We used TCGA 112 early stage PDAC patients to screen the prognostic value of UXT-AS1. Biological functions and mechanisms of UXT-AS1 were investigated by co-expression analysis, differentially expressed genes (DEGs) and gene set enrichment analysis, while targeted drug screening was investigated by connectivity Map (CMap).
Results: By analyzing the dataset from TCGA cohort, we found that UXT-AS1 was significantly up-regulated in pancreatic cancer tissues. Multivariate survival analysis demonstrated that PDAC patients with high UXT-AS1 expression had an unfavourable prognosis (adjusted P=0.033, HR=1.830, 95%CI=1.051-3.188). Genome-wide co-expression analysis and gene set enrichment analysis suggested that UXT-AS1 may act as a pivotal part in PDAC by participating in nuclear factor kappa beta, regulation of tumor necrosis factor, cell adhesion, T cell receptor signaling pathway, and numerous immune-related biological processes and signaling pathways. Functional enrichment analysis of DEGs between high- and low-UXT-AS1 expression groups suggested that these DEGs were significant enriched in B cell receptor complex, response to drug chemical carcinogenesis and drug metabolism-cytochrome P450. CMap analysis revealed that quipazine and terazosin may be targeted drugs for UXT-AS1 in PDAC.
Conclusion: Our current study has identified UXT-AS1 as a novel biomarker for the prognosis of early stage PDAC. We also clarified its biological functional mechanisms and identified two targeted drugs of UXT-AS1 in PDAC. © The author(s).

Entities:  

Keywords:  The Cancer Genome Atlas; UXT antisense RNA 1; pancreatic ductal adenocarcinoma; pancreaticoduodenectomy; prognosis

Year:  2021        PMID: 33754011      PMCID: PMC7974525          DOI: 10.7150/jca.46084

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  93 in total

1.  Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.

Authors:  Takayuki Toyonaga; Kenji Nakano; Masahiro Nagano; Gang Zhao; Koji Yamaguchi; Syoji Kuroki; Takashi Eguchi; Kazuo Chijiiwa; Masazumi Tsuneyoshi; Masao Tanaka
Journal:  Cancer Lett       Date:  2003-11-10       Impact factor: 8.679

2.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.

Authors: 
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

3.  Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review.

Authors:  Jonas R M Van Audenaerde; Geert Roeyen; Phillip K Darcy; Michael H Kershaw; M Peeters; Evelien L J Smits
Journal:  Pharmacol Ther       Date:  2018-04-13       Impact factor: 12.310

4.  Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line.

Authors:  Kee-Lung Chang; Hsiao-Ling Cheng; Li-Wen Huang; Bau-Shan Hsieh; Yu-Chen Hu; Tsai-Tung Chih; Huey-Wen Shyu; Shu-Jem Su
Journal:  Cancer Lett       Date:  2008-12-16       Impact factor: 8.679

5.  Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans.

Authors:  Marcus Schley; Sonja Ständer; John Kerner; Peter Vajkoczy; Guido Schüpfer; Martin Dusch; Martin Schmelz; Christoph Konrad
Journal:  Brain Res Bull       Date:  2009-02-06       Impact factor: 4.077

6.  Guggulsterone decreases proliferation and metastatic behavior of pancreatic cancer cells by modulating JAK/STAT and Src/FAK signaling.

Authors:  Muzafar A Macha; Satyanarayana Rachagani; Suprit Gupta; Priya Pai; Moorthy P Ponnusamy; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2013-08-03       Impact factor: 8.679

Review 7.  NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis.

Authors:  Anahid Jewett; Janko Kos; Yuman Fong; Meng-Wei Ko; Tahmineh Safaei; Milica Perišić Nanut; Kawaljit Kaur
Journal:  Semin Cancer Biol       Date:  2018-08-03       Impact factor: 15.707

8.  Allergen‑removed Rhus verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways.

Authors:  Youra Kang; Seong Woo Yoon; Byoungduck Park
Journal:  Oncol Rep       Date:  2018-09-12       Impact factor: 3.906

9.  Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells.

Authors:  Aino N E Salmiheimo; Harri K Mustonen; Sanna A A Vainionpää; Zhanlong Shen; Esko A J Kemppainen; Hanna E Seppänen; Pauli A Puolakkainen
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

Review 10.  Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer.

Authors:  Kartick C Pramanik; Monish Ram Makena; Kuntal Bhowmick; Manoj K Pandey
Journal:  Int J Mol Sci       Date:  2018-12-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.